Nutlin-3a

Catalog No.S8059

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Nutlin-3a Chemical Structure

Nutlin-3a Chemical Structure
Molecular Weight: 581.49

Validation & Quality Control

Quality Control & MSDS

Product Information

  • Compare Mdm2 Inhibitors
    Compare Mdm2 Products
  • Research Area

Product Description

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Targets p53/MDM2 interaction [3]
(Cell-free assay)
IC50 90 nM
In vitro Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MV-4-11MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHlR3VKSzVyPUCuOlEzOzdizszNMljGV2FPT0WU
H4MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnL3TWM2OD1yLk[2Nlgh|ryPM{XPOXNCVkeHUh?=
PA-1NX;I[3IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPhTWM2OD1yLki3NFk3KM7:TR?=NGjUS3lUSU6JRWK=
NKM-1M4DpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XWc2lEPTB;MT6wOFk{OSEQvF2=MXvTRW5ITVJ?
NEC8MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTFwMkG1O|Ih|ryPNHvIO5BUSU6JRWK=
EoL-1-cellNUnibHNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGeyeoFKSzVyPUGuNlY4ODFizszNM{LIOnNCVkeHUh?=
K5M2\pN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TZRWlEPTB;MT60NlA4OiEQvF2=M4L4ZXNCVkeHUh?=
QIMR-WILMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7aSGxKSzVyPUGuOlA5PTRizszNMnHyV2FPT0WU
MOLT-16NFjUVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHiTWM2OD1zLke4OlA1KM7:TR?=M17yNnNCVkeHUh?=
CHP-212M{XIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXaWJlWUUN3ME2xMlgyOzZ7IN88US=>M4PQTXNCVkeHUh?=
CTB-1NWnRS|AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTJwMEKyOFYh|ryPMV3TRW5ITVJ?
MOLT-4NWS3NFNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkP4TWM2OD1{LkOyPFU{KM7:TR?=NXnlUY85W0GQR1XS
A101DMlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrHWnVnUUN3ME2yMlM2ODFizszNMX7TRW5ITVJ?
DOHH-2MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDrTWM2OD1{LkSyNlc6KM7:TR?=Mo\1V2FPT0WU
ES4NWT2Oo82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHoTXE1UUN3ME2yMlQ{OTV3IN88US=>NYq0TlFPW0GQR1XS
SW780MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTJwNUC4PFMh|ryPMn:zV2FPT0WU
VA-ES-BJNH36dHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoCyTWM2OD1{LkW0NVEh|ryPM3X4TXNCVkeHUh?=
RPMI-8866NFLlfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnf2TWM2OD1{LkW2NlE1KM7:TR?=NIPJPZpUSU6JRWK=
ML-2MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHBTWM2OD1{LkW2OVc3KM7:TR?=NX\ZZ|JLW0GQR1XS
MSTO-211HMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHX0RmJKSzVyPUKuOVc1PTFizszNNXHTcXVxW0GQR1XS
JVM-3Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm[wTWM2OD1{LkW5N|I1KM7:TR?=MVTTRW5ITVJ?
A3-KAWNUPTUYdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fwVGlEPTB;Mj62NVgyQCEQvF2=NUm3NW9uW0GQR1XS
DK-MGMoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYSwTFBHUUN3ME2yMlYzPDdzIN88US=>M37HcXNCVkeHUh?=
LNCaP-Clone-FGCNG\nbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnkTWM2OD1{Lk[0N|E5KM7:TR?=MV\TRW5ITVJ?
HT-144NG\GUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TqbGlEPTB;Mj62OFU4PyEQvF2=NEn0[GpUSU6JRWK=
NB69MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{C5eGlEPTB;Mj62OVM{PCEQvF2=M4XpN3NCVkeHUh?=
A172NVq1cYZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3JTWM2OD1{Lk[3OVg5KM7:TR?=NG\rV5pUSU6JRWK=
RS4-11MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWX0[GNmUUN3ME2yMlczPDB5IN88US=>MnLxV2FPT0WU
DU-4475M1rzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTJwN{m1NFIh|ryPMkGxV2FPT0WU
SJSA-1MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHHTWM2OD1{LkiyOVU3KM7:TR?=MljBV2FPT0WU
BV-173MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTJwOES0N|kh|ryPMULTRW5ITVJ?
U-2-OSNY\NboU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnacFlQUUN3ME2yMlkyODdizszNMUPTRW5ITVJ?
CHP-134NH;zNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHIb5NIUUN3ME2yMlk{QDh{IN88US=>NYTidGJFW0GQR1XS
D-502MGMnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vwOmlEPTB;Mj65O|E2PCEQvF2=M2PC[HNCVkeHUh?=
KS-1MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPaTWM2OD1|LkCxOlI{KM7:TR?=M{HFTnNCVkeHUh?=
A204NVizZ4Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTNwMEW1PFgh|ryPNXXvVJpxW0GQR1XS
KGNM3PmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjlTWM2OD1|LkC4OFk3KM7:TR?=MYXTRW5ITVJ?
NCI-H292MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTNwMUKwNlgh|ryPMXvTRW5ITVJ?
CAKI-1NF7KTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37kTmlEPTB;Mz6xNlY6PCEQvF2=M3fNfHNCVkeHUh?=
C2BBe1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIf6[opKSzVyPUOuNVcxOjZizszNMniwV2FPT0WU
NB10NVq0Sm51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTNwMkC5OlYh|ryPM3rBN3NCVkeHUh?=
MHH-NB-11M4X3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4q3[WlEPTB;Mz6yOlgzPyEQvF2=NWfI[WVDW0GQR1XS
NCI-SNU-1M3jqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTNwMke4OFMh|ryPMULTRW5ITVJ?
HCT-116MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXDTWM2OD1|LkOwN|M2KM7:TR?=NVzScodIW0GQR1XS
G-401MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrVTWM2OD1|LkO2N|IzKM7:TR?=NX31WYVrW0GQR1XS
MN-60NHjFUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrkUZJFUUN3ME2zMlQ1ODl{IN88US=>NIfUb2VUSU6JRWK=
SW982NVTKZolqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3qU5RKSzVyPUOuOVA5PDhizszNM13senNCVkeHUh?=
RKOMo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fQfWlEPTB;Mz61N|k{PiEQvF2=M{LzTHNCVkeHUh?=
D-283MEDMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTNwNUe5PFYh|ryPM1vFZnNCVkeHUh?=
LB996-RCCM2q1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\UXXdEUUN3ME2zMlYzPTV6IN88US=>MoPlV2FPT0WU
A549M4jzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTNwNkO1OVIh|ryPM{i2NHNCVkeHUh?=
LB2241-RCCNYrtSWVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\VZmdDUUN3ME2zMlY2PzB6IN88US=>MUXTRW5ITVJ?
SK-HEP-1NULCXIJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fqUmlEPTB;Mz63OFI6PyEQvF2=NHG3UXNUSU6JRWK=
G-402MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vCUWlEPTB;Mz64NFg{OiEQvF2=Mn7vV2FPT0WU
GOTONYKyZ25jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfVOGVvUUN3ME2zMlg1OzN|IN88US=>NGS4O4RUSU6JRWK=
LOXIMVIMoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;mfGlEPTB;Mz64OVY4PSEQvF2=MkOzV2FPT0WU
NH-12NGDEO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLu[4s6UUN3ME20MlAyQTV7IN88US=>MXXTRW5ITVJ?
CTV-1M4ixdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTRwMEe5O|Mh|ryPM4HK[XNCVkeHUh?=
CP50-MEL-BMmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\GbmlEPTB;ND6yOFM6OiEQvF2=NETzPFVUSU6JRWK=
RH-18NIjhdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXITWM2OD12LkK3O|A3KM7:TR?=M3\ZN3NCVkeHUh?=
NB17MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjhb5NKSzVyPUSuN|E4PjhizszNMl3UV2FPT0WU
A375NET6cnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTRwM{O1NlQh|ryPM3ftOnNCVkeHUh?=
IST-MES1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTRwNEG0NVEh|ryPMV;TRW5ITVJ?
MZ2-MELNXL0O|V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LoTmlEPTB;ND61NFE2PSEQvF2=MnHmV2FPT0WU
CAL-54NGroRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fKNmlEPTB;ND61N|AyQSEQvF2=MYPTRW5ITVJ?
NCI-H28MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XlR2lEPTB;ND62NlcyPyEQvF2=Mm\kV2FPT0WU
D-247MGMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULXT4hEUUN3ME20Mlc2ODd{IN88US=>MU\TRW5ITVJ?
NCI-H460MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHH[WxKSzVyPUSuPVEyOjdizszNMUPTRW5ITVJ?
MCF7NX7j[4h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7pR|BKSzVyPUWuOFQzPDRizszNMmPmV2FPT0WU
697MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvIZVRIUUN3ME21MlQ1PTVizszNNFvWbZRUSU6JRWK=
ONS-76M1i1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTVwNUewNFkh|ryPM3LOd3NCVkeHUh?=
C32MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTVwNkCwNlkh|ryPNGq1T45USU6JRWK=
OS-RC-2NHW3TJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{[zfmlEPTB;NT63N|g5PyEQvF2=M1WwUnNCVkeHUh?=
MEL-HONWmxUGNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTVwOEW2Olch|ryPNUW1TZV[W0GQR1XS
LoVoM3vpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17XTGlEPTB;Nj6wNVYzPCEQvF2=MnTsV2FPT0WU
AGSNGPlVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFuxW25KSzVyPU[uNVQ5OjhizszNNHnU[HNUSU6JRWK=
GI-ME-NM1i3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTaSoJoUUN3ME22MlIzPDJzIN88US=>NXr1folmW0GQR1XS
H-EMC-SSMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEi1To1KSzVyPU[uN|g3KM7:TR?=M4jodHNCVkeHUh?=
RVH-421MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PBbWlEPTB;Nj60NlQzQCEQvF2=M3;LUnNCVkeHUh?=
SW954MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfsN5JKSzVyPU[uOVU2PzJizszNMXXTRW5ITVJ?
NB5Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjWWYxKSzVyPU[uOVYyQDNizszNM3zZZnNCVkeHUh?=
NCI-H2122MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvmV3lKSzVyPU[uOVg4QTNizszNM4\s[nNCVkeHUh?=
AM-38M1j2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTpUmFKSzVyPU[uO|U3OzlizszNMknwV2FPT0WU
KNS-81-FDNF;E[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1[3VGlEPTB;Nj63OlQ6PCEQvF2=M{LzbXNCVkeHUh?=
LS-513Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnoeXNKSzVyPU[uO|kxOjZizszNMoT6V2FPT0WU
A427M3;OZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUGzfodNUUN3ME22Mlg4QDJ7IN88US=>MUnTRW5ITVJ?
WM-115M4Tte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LIdGlEPTB;Nj65N|I{KM7:TR?=MUjTRW5ITVJ?
COLO-829MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\FVGlEPTB;Nz6yOFE5QCEQvF2=NWLJb49EW0GQR1XS
NCI-H1650M4LGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLNTWM2OD15LkO5NlI5KM7:TR?=NYrWSFZlW0GQR1XS
NCI-H358MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTdwNES4O|kh|ryPNULKWYFQW0GQR1XS
HT-1080NIXJRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXETWM2OD15LkS4NlU1KM7:TR?=NIrhW41USU6JRWK=
HCC2218MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTdwNkK5O{DPxE1?NX3vTVVVW0GQR1XS
NCI-H661MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTdwOEewOlkh|ryPMYnTRW5ITVJ?
KM-H2NX7QdndYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;mXW9KSzVyPUeuPFg3QTRizszNMkDkV2FPT0WU
RPMI-2650MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LFb2lEPTB;Nz65OFQyPCEQvF2=M4izZnNCVkeHUh?=
NCI-H226NFHuNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzyTWM2OD16LkKxNVIzKM7:TR?=MUnTRW5ITVJ?
MKN45MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTzTWM2OD16LkK2OlAzKM7:TR?=Mn7DV2FPT0WU
D-392MGMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPyPW5KSzVyPUiuOVI4OjJizszNNFnBWVNUSU6JRWK=
RCC10RGBMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fL[mlEPTB;OD64OlY6PSEQvF2=NFzjTXlUSU6JRWK=
CAL-51MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HjTGlEPTB;OT6xNFI2OSEQvF2=NF7zXWlUSU6JRWK=
COLO-678NUjOZYpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlSyTWM2OD17LkOyPFEyKM7:TR?=NXTiblE1W0GQR1XS
SK-MEL-24M4LBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH64TmFKSzVyPUmuOVU5PTZizszNM1fUZnNCVkeHUh?=
SK-MEL-30Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3JV|RKSzVyPUmuPVQ1PzZizszNMnHDV2FPT0WU
MMAC-SFMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzXOlBpUUN3ME2xNE4{QTZzIN88US=>NFXq[mVUSU6JRWK=
NTERA-S-cl-D1M{i5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTFyLk[1NFgh|ryPMWHTRW5ITVJ?
NB12M1:3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTFzLkWwN{DPxE1?NGT2NHdUSU6JRWK=
UACC-257MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTFzLki2PVUh|ryPMXfTRW5ITVJ?
LAN-6MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHwTWM2OD1zMT65PVI5KM7:TR?=NUDZSXhtW0GQR1XS
SW1573Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH31dopKSzVyPUGyMlMxQDZizszNNHXXS4lUSU6JRWK=
NMC-G1M1rSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknGTWM2OD1zMj60NVc2KM7:TR?=NH\6W29USU6JRWK=
SHP-77NXj2U3h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\Lc4xCUUN3ME2xNk42PTd2IN88US=>NXXj[HJ7W0GQR1XS
IGROV-1NVi2d2h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17iXGlEPTB;MUKuOlU4OyEQvF2=MW\TRW5ITVJ?
22RV1NFrL[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LjRmlEPTB;MUKuPFA2QSEQvF2=M2PJWHNCVkeHUh?=
SK-MEL-3NV\XXFNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTF|LkO5O|Mh|ryPM3;STnNCVkeHUh?=
NCI-H1563MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzVTWM2OD1zMz60NlAzKM7:TR?=MorvV2FPT0WU
IGR-1NYPWSo1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTF2LkCzOFch|ryPNV:2VXFyW0GQR1XS
EW-3NXzY[2xUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{n5WmlEPTB;MUSuNVY{QSEQvF2=MXnTRW5ITVJ?
JEG-3MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XtPWlEPTB;MUSuOFk2OyEQvF2=Ml7aV2FPT0WU
ES3NXvaO29FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITiZ3ZKSzVyPUG0MlY2PjJizszNMWjTRW5ITVJ?
MDA-MB-175-VIINFfYZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPPTWM2OD1zND63NVEyKM7:TR?=M2XpN3NCVkeHUh?=
P30-OHKNH[5PZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXITWM2OD1zNT6wOFk3KM7:TR?=NEDwV3RUSU6JRWK=
GP5dNEfxbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTF3LkG0OlYh|ryPNELV[nRUSU6JRWK=
HMV-IIMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnqeFZDUUN3ME2xOU4{OzN|IN88US=>MoLKV2FPT0WU
COLO-679NHzGOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13LXWlEPTB;MUWuOVAyKM7:TR?=NV7KcXJDW0GQR1XS
JARMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmruTWM2OD1zNT63NlA2KM7:TR?=MlnuV2FPT0WU
NCI-H1666MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfKOlg{UUN3ME2xOU46Ozl7IN88US=>MVvTRW5ITVJ?
SW48NV3mRZNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7aTWM2OD1zNT65OVE3KM7:TR?=MUPTRW5ITVJ?
NCI-H720M3HhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTF3Lkm5PFkh|ryPMVPTRW5ITVJ?
HT-1197NHLkXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELXVVJKSzVyPUG2MlA{PTJizszNMVvTRW5ITVJ?
HL-60NXyzVXVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTF4LkCzPFQh|ryPMY\TRW5ITVJ?
BENM4HjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HqWWlEPTB;MU[uOVY{QCEQvF2=NUXrfYJqW0GQR1XS
HAL-01NGTRVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jiNWlEPTB;MU[uPFkxQSEQvF2=MoO3V2FPT0WU
SW900NGXpTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jsTWlEPTB;MU[uPVE{OiEQvF2=NIXROG1USU6JRWK=
SBC-1NVLuWZdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTF5LkW0Nlkh|ryPMlfIV2FPT0WU
SH-4M3;KT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DYeWlEPTB;MUeuOVg1OSEQvF2=MlLkV2FPT0WU
UACC-62MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3v1d2lEPTB;MUeuO|Y{PyEQvF2=NUTnZYVHW0GQR1XS
BHT-101NWjTc|ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjjVZZKSzVyPUG5Mlg4ODVizszNM3XCVHNCVkeHUh?=
DBNXWwbms5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYH4TG1bUUN3ME2yNU42PjR7IN88US=>NIjEWYVUSU6JRWK=
SK-MEL-1M2D0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvifmJKSzVyPUKxMlU5PzJizszNM3\vPHNCVkeHUh?=
NCI-H747Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXYTWM2OD1{Mj63N|c6KM7:TR?=NWrCdnl4W0GQR1XS
SK-LU-1M{HrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHV[ndmUUN3ME2yN{4{PTJ2IN88US=>MXjTRW5ITVJ?
KG-1NV3BTFRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPPTWM2OD1{Mz60PVQ3KM7:TR?=NX3r[2ZKW0GQR1XS
LXF-289M17VeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTJ|LkexOEDPxE1?M4XSWXNCVkeHUh?=
HCC1954MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPTUIhKSzVyPUK0Mlg5PDRizszNNWDUUXlwW0GQR1XS
Ramos-2G6-4C10NEjLdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfP[nViUUN3ME2yOk41QThzIN88US=>NWLBc3dvW0GQR1XS
DBTRG-05MGMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofWTWM2OD1{Nj62OFg5KM7:TR?=NFKwcldUSU6JRWK=
NCI-H2052NVzXVG9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTJ5LkW2PFQh|ryPNGP0VJlUSU6JRWK=
RMG-INWr3XpU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XCPGlEPTB;MkmuOFE{QSEQvF2=MYfTRW5ITVJ?
H9MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkmwTWM2OD1|MT6zNFA5KM7:TR?=M{fHeXNCVkeHUh?=
GR-STMnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXCPXlKSzVyPUOyMlQ1PTNizszNMn7EV2FPT0WU
Mo-TNYfDSIw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXtTWM2OD1|Mj61NFQ3KM7:TR?=M3fVOXNCVkeHUh?=
SW1088M2fn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLkWJVKSzVyPUOyMlk5ODFizszNNFHWVVVUSU6JRWK=
LB2518-MELNH;rW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYWw[lJYUUN3ME2zN{4xPzl5IN88US=>NUHXVGtvW0GQR1XS
NCI-H82NFnQSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTN|LkG2OlEh|ryPM{n6dXNCVkeHUh?=
LAMA-84Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVz6SmY2UUN3ME2zOE43ODd|IN88US=>NFvyWVVUSU6JRWK=
KYSE-450NWW5ToZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\GUmh6UUN3ME2zOE43Pzd4IN88US=>NVHF[VZKW0GQR1XS
LU-99AMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmmwTWM2OD1|NT6wNFA4KM7:TR?=NYPWSYZGW0GQR1XS
BE-13NH22O5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXFWppKSzVyPUO1MlY2PDVizszNM17F[HNCVkeHUh?=
GAKMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17GPGlEPTB;M{WuOlk2KM7:TR?=MmK1V2FPT0WU
NCI-H1573NUDRRpl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFyxbm5KSzVyPUO1Mlg5OThizszNMV\TRW5ITVJ?
AsPC-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTq[o5KSzVyPUO2MlE2OjdizszNM3L1cXNCVkeHUh?=
HDLM-2NIn3Z3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPmb2NKSzVyPUO2MlMyPiEQvF2=NGfDO3NUSU6JRWK=
NCI-H441MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFT4N|ZKSzVyPUO3MlA3QTFizszNNHnyNnlUSU6JRWK=
CAL-27NV\3W3ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1G4ZmlEPTB;M{euO|I{OSEQvF2=MVnTRW5ITVJ?
OVCAR-3MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlT2TWM2OD1|OT6zNVgyKM7:TR?=Mk\SV2FPT0WU
RPMI-8226M2W0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPkTWM2OD1|OT61PVgh|ryPNYPnU45ZW0GQR1XS
EFO-21M4nFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILlWoxKSzVyPUSwMlU5OTRizszNMl;ZV2FPT0WU
SNU-C2BMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLFTWM2OD12MT61NFg1KM7:TR?=MkLiV2FPT0WU
VM-CUB-1M2LYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7WTnBKSzVyPUSzMlgxOzdizszNMn[xV2FPT0WU
NCI-H2087MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLSRlhKSzVyPUS1MlAzOzNizszNNX:1[YRXW0GQR1XS
EW-16M{G3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\NTWM2OD12Nj6zNVM4KM7:TR?=M124U3NCVkeHUh?=
SK-N-ASMk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3PTWM2OD12Nj63NVY4KM7:TR?=NUHBO5NrW0GQR1XS
COR-L105NH3WT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fjVWlEPTB;NE[uPFg2PyEQvF2=NVzQXZY3W0GQR1XS
DELM2PvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTR6LkC0Nlkh|ryPM2nPTXNCVkeHUh?=
JVM-2M17sS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jwWGlEPTB;NEiuNFU2QCEQvF2=NFnCXJBUSU6JRWK=
KARPAS-45MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTR7LkS1N|gh|ryPNETkboJUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.

Protocol(Only for Reference)

Kinase Assay: [3]

Biacore studies Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel

Cell Assay: [2]

Cell lines OSA, T778, RMS13, U2OS, SaOS-2
Concentrations ~5 μM
Incubation Time 120 h
Method SRB

Animal Study: [1]

Animal Models SJSA-1 xenograft
Formulation 1% Klucel, 0.1% Tween 80
Dosages 50, 100, 200 mg/kg twice daily
Administration oral

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tovar C, et al. Proc Natl Acad Sci U S A, 2006, 103(6), 1888-1893.

[2] Ohnstad HO, et al. BMC Cancer, 2011, 11(211), 1-11.

view more

Chemical Information

Molecular Weight (MW) 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms (-)-Nutlin-3
Solubility (25°C) * In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water <1 mg/mL (<1 mM)
In vivo 2% DMSO+1% hydroxyethyl cellulose+0.2% Tween 80 15 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-Piperazinone, 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Mdm2 Products

  • Idasanutlin (RG-7388)

    Idasanutlin (RG-7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • Nutlin-3

    Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

  • NSC 207895

    NSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.

  • Nutlin-3b

    Nutlin-3b is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a.

  • YH239-EE

    YH239-EE, the ethyl ester of YH239, is a potent p53-MDM2 antagonist and an apoptosis inducer.

  • Z-VAD-FMK

    Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

    Features:A key compound for apoptosis studies.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

Recently Viewed Items

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us